How Clover’s 17% Revenue Jump Signals a Nutritional Ingredients Breakout
Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.
- 1H FY26 revenue rises to $44.1 million, up 17%
- Gross margin improves to 35.6%, up 850 basis points
- EBITDA increases to $6.9 million, NPAT reaches $4.2 million
- Interim dividend declared at 1.0 cent per share
- FY26 revenue guidance set between $92 million and $96 million
Strong Financial Momentum
Clover Corporation Limited (ASX:CLV), a specialist in nutritional ingredients, has delivered a strong first half performance for FY26, reporting revenue of $44.1 million, a 17% increase from $37.6 million in the prior corresponding period. This growth was driven by a recovery in key markets across Europe and Australia-New Zealand (ANZ), supported by both existing customer expansion and new client acquisitions.
Notably, the company’s gross margin improved markedly to 35.6%, up 850 basis points from 27.1% in 1H FY25. This margin expansion reflects a favourable shift in product mix and enhanced manufacturing efficiencies. EBITDA rose significantly to $6.9 million, up from $4.3 million, while net profit after tax (NPAT) increased to $4.2 million, nearly doubling the previous year’s $2.4 million.
Operational Highlights and Strategic Investments
Operationally, Clover’s strategic investment in Melody Dairies in New Zealand is paying dividends, with improved plant utilisation and cost efficiencies despite currency headwinds from a stronger Australian dollar. The joint venture continues to meet revised banking covenants, signalling financial stability.
In Ecuador, the extraction of crude fish oil from tuna heads remains steady, contributing about 30% of the company’s tuna oil inputs. Clover is actively negotiating to secure additional supply to support further volume growth, indicating a focus on scaling raw material sourcing.
On the innovation front, Clover is advancing regulatory approvals for its Premneo DHA emulsion, with clinical trials planned in India and ongoing regulatory engagement in Singapore, Canada, and the EU. The product has received positive expert panel feedback, with no safety concerns raised, positioning it as a promising addition to Clover’s portfolio.
Additionally, Clover is progressing new product development, including CholineXcel, a unique flowable powder undergoing customer trials and patent filing preparations. The company is also expanding its DHA and ARA omega fatty acid offerings, capitalising on competitor supply disruptions and diversifying packaging formats to capture market share.
Outlook and Market Positioning
Looking ahead, Clover’s board projects continued momentum into the second half of FY26, with revenue guidance set between $92 million and $96 million. This optimistic outlook is contingent on stable geopolitical conditions and uninterrupted supply chains, which remain potential risk factors.
CEO Peter Davey emphasised the strategic shift towards a more diversified product portfolio and broader human nutrition segments, including seniors, toddlers, and adult nutrition. This diversification aims to reduce reliance on any single market and build a more resilient revenue base aligned with structural growth trends.
Bottom Line?
Clover’s strong half-year results and strategic innovation pipeline set the stage for sustained growth, but upcoming regulatory milestones and supply chain stability will be key to watch.
Questions in the middle?
- How will regulatory approvals for Premneo impact Clover’s market expansion and revenue?
- Can Clover secure additional tuna head supply in Ecuador to support volume growth?
- What is the potential market impact of competitor product recalls on Clover’s ARA sales?
